Douglas Elliman Q2 FY26 net loss narrows to $2.7 million; revenue rises 4.5% year over year to $283.4 million
Reuters2026/08/07 11:04- Douglas Elliman posts Q2 revenue up 4.5% year over year to USD 283.4 million.
- Operating loss narrows to USD 3.4 million; net loss attributable to shareholders narrows to USD 2.7 million, or USD 0.03 a share.
- Gross transaction value rises 5.9% to USD 10.8 billion; adjusted EBITDA loss (non-GAAP) narrows to USD 1 million from USD 3.6 million.
- Ends June 30 with USD 105.2 million cash and no long-term debt; development marketing pipeline totals USD 26.1 billion.
- Launches AI transformation using Google Cloud, including new intelligence unit Elius; expands in France to 15 offices with a Paris opening.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.
Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.
Fogo Foundation Attacked, Approximately 400 Million FOGO Tokens Transferred
Blue Owl (OWL.US) teams up with PIMCO to tailor a $2.4 billion GPU financing for IREN (IREN.US)
A $2.4 billions debt financing round, led by funds under Blue Owl Capital Inc., has been finalized. The funds will be allocated to cloud service provider IREN Ltd. to purchase NVIDIA's Blackwell Ultra GPUs, supporting the development of its data center campus in Canada.
Crypto prices
More
